PARP inhibitors may be novel treatment strategy in women with HER2-positive breast ca

[News]

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

More... (http://www.news-medical.net/news/20120917/PARP-inhibitors-may-be-novel-treatment-strategy-in-women-with-HER2-positive-breast-cancers.aspx)